Aprea Therapeutics (NASDAQ:APRE) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Aprea Therapeutics (NASDAQ:APRE) issued its quarterly earnings results on Tuesday. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.20, Zacks reports. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.15 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%.

Aprea Therapeutics Trading Up 2.3 %

Shares of APRE stock opened at $2.24 on Thursday. The firm has a fifty day simple moving average of $3.10 and a 200-day simple moving average of $3.25. The company has a market capitalization of $12.17 million, a PE ratio of -0.80 and a beta of 0.82. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $6.80.

Analyst Ratings Changes

A number of equities analysts have weighed in on APRE shares. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.